Berlin - Delayed Quote EUR

Savara Inc (YB4P.BE)

2.8200

+0.0600

+(2.17%)

At close: April 30 at 8:08:33 AM GMT+2

Savara Announces New Employment Inducement Grant

LANGHORNE, Pa., April 11, 2025--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to seven new employees.

Business Wire 19 days ago

SVRA
Savara Announces Encore Presentations From the Phase 3 IMPALA-2 Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients With Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at Two Upcoming Scientific Conferences

LANGHORNE, Pa., April 07, 2025--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical-stage biopharmaceutical company focused on rare respiratory diseases, announced encore presentations of top-line data from the pivotal, Phase 3 IMPALA-2 clinical trial of molgramostim in aPAP will be presented at the 65th Congress of the German Society of Pneumology (DGP) in Leipzig, Germany taking place April 9-12 and at the 65th Annual Meeting of the Japanese Respiratory Society (JRS) taking place April 11-13,

Business Wire 23 days ago

SVRA
Savara Reports Fourth Quarter and Year End 2024 Financial Results and Provides Business Update

LANGHORNE, Pa., March 27, 2025--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, reported financial results for the fourth quarter and full year ending December 31, 2024 and provided a business update.

Business Wire last month

SVRA
Savara Gets Up to $200 Million Loan From Hercules Capital

Savara (SVRA) said Wednesday it entered into a loan and security agreement of up to $200 million wit

PREMIUM
MT Newswires last month

SVRA

HTGC
Savara Enters Into Non-Dilutive Debt Financing for up to $200M With Hercules Capital

LANGHORNE, Pa., March 26, 2025--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that it has entered into a loan and security agreement with Hercules Capital, Inc. (NYSE: HTGC), for up to $200 million. Access to the additional capital strengthens Savara’s balance sheet following the submission of the Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for MOLBREEVI* as a treat

Business Wire last month

SVRA
Savara Completes Submission of the Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for MOLBREEVI* as a Treatment for Autoimmune Pulmonary Alveolar Proteinosis (aPAP)

LANGHORNE, Pa., March 26, 2025--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that it has completed submission of the BLA to the FDA for MOLBREEVI as a treatment for aPAP.

Business Wire last month

SVRA
Savara to Present New Data From the Phase 3 IMPALA-2 Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients With Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the American Thoracic Society International Conference 2025

LANGHORNE, Pa., March 17, 2025--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical-stage biopharmaceutical company focused on rare respiratory diseases, today announced the acceptance of two abstracts for poster presentation at the American Thoracic Society (ATS) International Conference taking place May 16-21, 2025, in San Francisco, CA. The Company will also host an Industry Theater titled "Advances in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)" at the meeting.

Business Wire last month

SVRA
Savara Announces U.S. Launch of the aPAP ClearPath™ Dried Blood Spot Test to Detect Autoimmune Pulmonary Alveolar Proteinosis (aPAP)

LANGHORNE, Pa., March 06, 2025--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, announced the launch of the aPAP ClearPath Dried Blood Spot (DBS) Test in the U.S., an evolution of the first serum-based assay the Company launched. The DBS test helps obtain a diagnosis of aPAP, a rare autoimmune lung disease caused by antibodies targeting GM-CSF, with only a finger-prick blood sample.

Business Wire last month

SVRA
Savara Announces Participation in the Leerink Global Healthcare Conference

LANGHORNE, Pa., March 03, 2025--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that members of its management team will attend the Leerink Global Healthcare Conference and participate in a fireside chat on Tuesday, March 11th, 10:40am ET/7:40am PT.

Business Wire last month

SVRA
Positive Signs As Multiple Insiders Buy Savara Stock

Usually, when one insider buys stock, it might not be a monumental event. But when multiple insiders are buying like...

Simply Wall St. 2 months ago

SVRA
Savara Announces Manuscript on Long-Term Outcomes With Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Published in ERJ Open Research

LANGHORNE, Pa., January 30, 2025--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced a manuscript titled, "Long-Term Outcomes in Five Patients with Autoimmune Pulmonary Alveolar Proteinosis Treated with Molgramostim Inhalation Solution" was published online in the journal ERJ Open Research. The outcomes data presented suggest that treatment with molgramostim addresses the underlying pathophysiology of aPAP, r

Business Wire 2 months ago

SVRA
Savara Announces Participation in Upcoming Healthcare Investor Conferences

LANGHORNE, Pa., January 29, 2025--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that members of its management team will be attending two upcoming healthcare investor conferences and participating in fireside chats at each.

Business Wire 2 months ago

SVRA
Savara Inc. (NASDAQ:SVRA) is largely controlled by institutional shareholders who own 53% of the company

Key Insights Given the large stake in the stock by institutions, Savara's stock price might be vulnerable to their...

Simply Wall St. 3 months ago

SVRA
Savara Initiates Rolling Submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for MOLBREEVI* for the Potential Treatment of Autoimmune Pulmonary Alveolar Proteinosis (aPAP)

LANGHORNE, Pa., December 18, 2024--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, initiated a rolling submission of a BLA to the FDA for MOLBREEVI for the potential treatment of aPAP, a chronic and debilitating rare lung disease characterized by the abnormal build-up of surfactant in the alveoli of the lungs.

Business Wire 4 months ago

SVRA
Savara Announces Participation in the 43rd Annual J.P. Morgan Healthcare Conference

LANGHORNE, Pa., December 17, 2024--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that the Company will present and host 1x1 meetings at the 43rd Annual J.P. Morgan Healthcare Conference.

Business Wire 4 months ago

SVRA
Estimating The Fair Value Of Savara Inc. (NASDAQ:SVRA)

Key Insights Using the 2 Stage Free Cash Flow to Equity, Savara fair value estimate is US$3.72 Current share price of...

Simply Wall St. 5 months ago

SVRA
Savara Announces Encore Presentation of Results from the Phase 3 IMPALA-2 Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the British Thoracic Society Winter Meeting 2024

LANGHORNE, Pa., November 22, 2024--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that an encore presentation of results from the pivotal, Phase 3 IMPALA-2 trial will be presented at the British Thoracic Society (BTS) Winter Meeting, taking place November 27-29, 2024, in London, England.

Business Wire 5 months ago

SVRA
Evercore Downgrades Savara on Manufacturing Concerns for Lung Disease Drug Candidate

Analyst Liisa Bayko also slashed Savara's price target

GuruFocus.com 5 months ago

SVRA
Savara Announces Participation in Upcoming Healthcare Conferences

LANGHORNE, Pa., November 13, 2024--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that members of its management team will be attending the below listed upcoming healthcare conferences and participating in fireside chats.

Business Wire 5 months ago

SVRA
Savara Reports Third Quarter 2024 Financial Results and Provides Business Update

LANGHORNE, Pa., November 12, 2024--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, reported financial results for the third quarter ending September 30, 2024 and provided a business update.

Business Wire 5 months ago

SVRA

Performance Overview

Return	YB4P.BE	S&P 500 (^GSPC)
YTD	-4.73%	-4.17%
1-Year	-33.80%	+12.32%
3-Year	+159.07%	+36.42%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Savara Inc (YB4P.BE)

Savara Announces New Employment Inducement Grant

Savara Announces Encore Presentations From the Phase 3 IMPALA-2 Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients With Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at Two Upcoming Scientific Conferences

Savara Reports Fourth Quarter and Year End 2024 Financial Results and Provides Business Update

Savara Gets Up to $200 Million Loan From Hercules Capital

Savara Enters Into Non-Dilutive Debt Financing for up to $200M With Hercules Capital

Savara Completes Submission of the Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for MOLBREEVI* as a Treatment for Autoimmune Pulmonary Alveolar Proteinosis (aPAP)

Savara to Present New Data From the Phase 3 IMPALA-2 Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients With Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the American Thoracic Society International Conference 2025

Savara Announces U.S. Launch of the aPAP ClearPath™ Dried Blood Spot Test to Detect Autoimmune Pulmonary Alveolar Proteinosis (aPAP)

Savara Announces Participation in the Leerink Global Healthcare Conference

Positive Signs As Multiple Insiders Buy Savara Stock

Savara Announces Manuscript on Long-Term Outcomes With Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Published in ERJ Open Research

Savara Announces Participation in Upcoming Healthcare Investor Conferences

Savara Inc. (NASDAQ:SVRA) is largely controlled by institutional shareholders who own 53% of the company

Savara Initiates Rolling Submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for MOLBREEVI* for the Potential Treatment of Autoimmune Pulmonary Alveolar Proteinosis (aPAP)

Savara Announces Participation in the 43rd Annual J.P. Morgan Healthcare Conference

Estimating The Fair Value Of Savara Inc. (NASDAQ:SVRA)

Savara Announces Encore Presentation of Results from the Phase 3 IMPALA-2 Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the British Thoracic Society Winter Meeting 2024

Evercore Downgrades Savara on Manufacturing Concerns for Lung Disease Drug Candidate

Savara Announces Participation in Upcoming Healthcare Conferences

Savara Reports Third Quarter 2024 Financial Results and Provides Business Update

Performance Overview